VRXAW
Veraxa Biotech AG • NASDAQ
$0.12 ▼ -7.70% (-0.01)
VRXAW
Veraxa Biotech AGNASDAQ • $0.12 ▼ -7.70% (-0.01)
Market Cap $3.06 M
52w High $0.12
52w Low $0.12
P/E 0
Volume 1.59K
Outstanding Shares 25.30M
Market Cap $3.06 M
52w High $0.12
52w Low $0.12
P/E 0
Volume 1.59K
Outstanding Shares 25.30M
About Veraxa Biotech AG
https://www.veraxa.comVeraxa Biotech AG is a clinical-stage biopharmaceutical company specializing in next-generation antibody-based cancer therapies. [9] The company is advancing a drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. [14] It was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). [8, 14].
CEO
Christoph Antz
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public June 10, 2026
Method of going public SPAC
Full time employees 0
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0